Clinical journal of the American Society of Nephrology : CJASN
-
Clin J Am Soc Nephrol · Nov 2020
Utilization of Deep Learning for Subphenotype Identification in Sepsis-Associated Acute Kidney Injury.
Sepsis-associated AKI is a heterogeneous clinical entity. We aimed to agnostically identify sepsis-associated AKI subphenotypes using deep learning on routinely collected data in electronic health records. ⋯ Utilizing routinely collected laboratory variables, vital signs, and comorbidities, we were able to identify three distinct subphenotypes of sepsis-associated AKI with differing outcomes.
-
Clin J Am Soc Nephrol · Nov 2020
Prevalence of Kidney Injury and Associations with Critical Illness and Death in Patients with COVID-19.
Coronavirus disease 2019 is spreading rapidly across the world. This study aimed to assess the characteristics of kidney injury and its association with disease progression and death of patients with coronavirus disease 2019. ⋯ This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2020_09_18_CJN04780420.mp3.
-
Clin J Am Soc Nephrol · Oct 2020
Observational StudyThe Incidence, Risk Factors, and Prognosis of Acute Kidney Injury in Adult Patients with Coronavirus Disease 2019.
Since December 2019, coronavirus disease 2019 (COVID-19) outbreak occurred and has rapidly spread worldwide. However, little information is available about the AKI in COVID-19. We aimed to evaluate the incidence, risk factors, and prognosis of AKI in adult patients with COVID-19. ⋯ AKI is uncommon but carries high in-hospital mortality in patients with COVID-19.
-
Clin J Am Soc Nephrol · Aug 2020
Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates genes related to iron metabolism. The efficacy (noninferiority) and safety of daprodustat compared with standard therapy (darbepoetin alfa) was evaluated. ⋯ 201754, Clinicaltrials.gov, NCT02969655.